Details:
The goal of the collaboration is to provide biological resources from HSC patients in order to evaluate MALT1-targeted therapeutics, including Rheos’s lead product candidate, RHX-317, for Graft-versus-Host Disease, based on functional immunologic profiling of patients.
Lead Product(s): RHX-317
Therapeutic Area: Immunology Product Name: RHX-317
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Rheos Medicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 27, 2021